Pharsight

Otrexup generic

Otrexup is an anti-rheumatic drug owned by Otter Pharms. It was first authorized for market use on 11 October, 2013. The drug contains methotrexate as its active ingredient and is available in solution;subcutaneous dosage forms.

When will Otrexup generic be available?

The generic version of Otrexup could become available after 27 May, 2031 which marks the expiry date of the last patent. The early release of the Otrexup generic may be possible through a Para IV filing, which allows generic manufacturers to challenge the validity of the patents.

Otrexup uses

Otrexup is primarily used as a subcutaneous injection of methotrexate. The active ingredient, methotrexate, works by reducing the effects of the body's immune system, making it effective in treating certain types of cancer, severe psoriasis, and rheumatoid arthritis.

Otrexup patent expiration

Otrexup is protected by 14 patents, with none expired so far. The patents cover innovations in both the drug formulation and delivery method. The last patent, titled 'Injector safety device,' is due to expire on May 27, 2031, after which the Otrexup generic may be released. Below are the details of the patents:

EPO Oppostions filed on Otrexup

Otrexup dosage

Want to ask something?